Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics

References

• Kawamura K, Kouki T, Kawahara G, Kikuyama S. Hypophyseal development in vertebrates from amphibians to mammals. Gen. Comp. Endocrinol.126(2), 130–135 (2002).
   PubMed Web of Science ®Google Scholar
• Moore ES, Ward RE, Jamison PL, Morris CA, Bader PI, Hall BD. The subtle facial signs of prenatal exposure to alcohol: an anthropometric approach. J. Pediatr.139(2), 215–219 (2001).
   PubMed Web of Science ®Google Scholar
• Faglia G, Spada A. Genesis of pituitary adenomas: state of the art. J. Neurooncol.54(2), 95–110 (2001).
   PubMed Web of Science ®Google Scholar
• Zhu X, Gleiberman AS, Rosenfeld MG. Molecular physiology of pituitary development: signaling and transcriptional networks. Physiol. Rev.87(3), 933–963 (2007).
   PubMed Web of Science ®Google Scholar
• Bunin GR, Surawicz TS, Witman PA, Preston-Martin S, Davis F, Bruner JM. The descriptive epidemiology of craniopharyngioma. J. Neurosurg.89(4), 547–551 (1998).
   PubMed Web of Science ®Google Scholar
• Jagannathan J, Kanter AS, Sheehan JP, Jane JA Jr, Laws ER Jr. Benign brain tumors: sellar/parasellar tumors. Neurol. Clin.25(4), 1231–1249, xi (2007).
   PubMed Web of Science ®Google Scholar
• Rienstein S, Adams EF, Pilzer D, Goldring AA, Goldman B, Friedman E. Comparative genomic hybridization analysis of craniopharyngiomas. J. Neurosurg.98(1), 162–164 (2003).
   PubMed Web of Science ®Google Scholar
• Karnes PS, Tran TN, Cui MY et al. Cytogenetic analysis of 39 pediatric central nervous system tumors. Cancer Genet. Cytogenet.59(1), 12–19 (1992).
   PubMed Web of Science ®Google Scholar
• Sekine S, Shibata T, Kokubu A et al. Craniopharyngiomas of adamantinomatous type harbor β-catenin gene mutations. Am. J. Pathol.161(6), 1997–2001 (2002).
   PubMed Web of Science ®Google Scholar
• Adamson TE, Wiestler OD, Kleihues P, Yasargil MG. Correlation of clinical and pathological features in surgically treated craniopharyngiomas. J. Neurosurg.73(1), 12–17 (1990).
   PubMed Web of Science ®Google Scholar
• Yasargil MG, Curcic M, Kis M, Siegenthaler G, Teddy PJ, Roth P. Total removal of craniopharyngiomas. Approaches and long-term results in 144 patients.J. Neurosurg.73(1), 3–11 (1990).
   PubMed Web of Science ®Google Scholar
• Thomsett MJ, Conte FA, Kaplan SL, Grumbach MM. Endocrine and neurologic outcome in childhood craniopharyngioma: Review of effect of treatment in 42 patients. J. Pediatr.97(5), 728–735 (1980).
   PubMed Web of Science ®Google Scholar
• Scott RM, Hetelekidis S, Barnes PD, Goumnerova L, Tarbell NJ. Surgery, radiation, and combination therapy in the treatment of childhood craniopharyngioma – a 20-year experience. Pediatr. Neurosurg.21(Suppl. 1), 75–81 (1994).
   PubMed Web of Science ®Google Scholar
• Sanford RA. Craniopharyngioma: results of survey of the American Society of Pediatric Neurosurgery. Pediatr. Neurosurg.21(Suppl. 1), 39–43 (1994).
   PubMed Web of Science ®Google Scholar
• Fahlbusch R, Honegger J, Paulus W, Huk W, Buchfelder M. Surgical treatment of craniopharyngiomas: experience with 168 patients. J. Neurosurg.90(2), 237–250 (1999).
   PubMed Web of Science ®Google Scholar
• Hetelekidis S, Barnes PD, Tao ML et al. 20-year experience in childhood craniopharyngioma. Int. J. Radiat. Oncol. Biol. Phys.27(2), 189–195 (1993).
   PubMedGoogle Scholar
• Asa SL, Ezzat S. The pathogenesis of pituitary tumours. Nat. Rev. Cancer2(11), 836–849 (2002).
   PubMed Web of Science ®Google Scholar
• Ezzat S, Asa SL, Couldwell WT et al. The prevalence of pituitary adenomas: a systematic review. Cancer101(3), 613–619 (2004).
   PubMed Web of Science ®Google Scholar
• Burrow GN, Wortzman G, Rewcastle NB, Holgate RC, Kovacs K. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. N. Engl. J. Med.304(3), 156–158 (1981).
   PubMed Web of Science ®Google Scholar
• Artese R, D’Osvaldo DH, Molocznik I et al. Pituitary tumors in adolescent patients. Neurol. Res.20(5), 415–417 (1998).
   PubMed Web of Science ®Google Scholar
• Abe T, Tara LA, Ludecke DK. Growth hormone-secreting pituitary adenomas in childhood and adolescence: features and results of transnasal surgery. Neurosurgery45(1), 1–10 (1999).
   PubMed Web of Science ®Google Scholar
• Kane LA, Leinung MC, Scheithauer BW et al. Pituitary adenomas in childhood and adolescence. J. Clin. Endocrinol. Metab.79(4), 1135–1140 (1994).
   PubMed Web of Science ®Google Scholar
• Alexander JM, Biller BM, Bikkal H, Zervas NT, Arnold A, Klibanski A. Clinically nonfunctioning pituitary tumors are monoclonal in origin. J. Clin. Invest.86(1), 336–340 (1990).
   PubMed Web of Science ®Google Scholar
• Spada A, Mantovani G, Lania A. Pathogenesis of prolactinomas. Pituitary8(1), 7–15 (2005).
   PubMedGoogle Scholar
• Ezzat S, Asa SL. Mechanisms of disease: the pathogenesis of pituitary tumors. Nat. Clin. Pract. Endocrinol. Metab.2(4), 220–230 (2006).
   PubMedGoogle Scholar
• Melmed S. Mechanisms for pituitary tumorigenesis: the plastic pituitary. J. Clin. Invest.112(11), 1603–1618 (2003).
   PubMed Web of Science ®Google Scholar
• Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S. Clonal origin of pituitary adenomas. J. Clin. Endocrinol. Metab.71(6), 1427–1433 (1990).
   PubMed Web of Science ®Google Scholar
• Heaney AP, Melmed S. Molecular targets in pituitary tumours. Nat. Rev. Cancer4(4), 285–295 (2004).
   PubMed Web of Science ®Google Scholar
• Marx SJ, Agarwal SK, Kester MB et al. Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias. Recent Prog. Horm. Res.54, 397–438; discussion 438–439 (1999).
   PubMedGoogle Scholar
• Verges B, Boureille F, Goudet P et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J. Clin. Endocrinol. Metab.87(2), 457–465 (2002).
   PubMed Web of Science ®Google Scholar
• Abe T, Yoshimoto K, Taniyama M et al. An unusual kindred of the multiple endocrine neoplasia type 1 (MEN1) in Japanese. J. Clin. Endocrinol. Metab.85(3), 1327–1330 (2000).
   PubMed Web of Science ®Google Scholar
• Horvath A, Stratakis CA. Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors. Rev. Endocr. Metab. Disord.9(1), 1–11 (2008).
   PubMed Web of Science ®Google Scholar
• Kirschner LS, Sandrini F, Monbo J, Lin JP, Carney JA, Stratakis CA. Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the carney complex. Hum. Mol. Genet.9(20), 3037–3046 (2000).
   PubMed Web of Science ®Google Scholar
• Pack SD, Kirschner LS, Pak E, Zhuang Z, Carney JA, Stratakis CA. Genetic and histologic studies of somatomammotropic pituitary tumors in patients with the “complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas” (Carney complex). J. Clin. Endocrinol. Metab.85(10), 3860–3865 (2000).
   PubMed Web of Science ®Google Scholar
• Stratakis CA, Matyakhina L, Courkoutsakis N et al. Pathology and molecular genetics of the pituitary gland in patients with the ‘complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas’ (Carney complex). Front. Horm. Res.32, 253–264 (2004).
   PubMed Web of Science ®Google Scholar
• Beckers A, Daly AF. The clinical, pathological, and genetic features of familial isolated pituitary adenomas. Eur. J. Endocrinol.157(4), 371–382 (2007).
   PubMed Web of Science ®Google Scholar
• Stergiopoulos SG, Abu-Asab MS, Tsokos M, Stratakis CA. Pituitary pathology in Carney complex patients. Pituitary7(2), 73–82 (2004).
   PubMedGoogle Scholar
• Abe T, Ludecke DK, Saeger W. Clinically nonsecreting pituitary adenomas in childhood and adolescence. Neurosurgery42(4), 744–741 (1998).
   PubMed Web of Science ®Google Scholar
• Ortiz-Suarez H, Erickson DL. Pituitary adenomas of adolescents. J. Neurosurg.43(4), 437–439 (1975).
   PubMed Web of Science ®Google Scholar
• Fraioli B, Ferrante L, Celli P. Pituitary adenomas with onset during puberty. Features and treatment. J. Neurosurg.59(4), 590–595 (1983).
   PubMed Web of Science ®Google Scholar
• Laws ER, Scheithauer BW, Groover RV. Pituitary adenomas in childhood and adolescence. Prog. Exp. Tumor Res.30, 359–361 (1987).
   PubMed Web of Science ®Google Scholar
• Gaini SM, Tomei G, Arienta C, Zavanone M, Giovanelli M, Villani R. Optic nerve and chiasm gliomas in children. J. Neurosurg. Sci.26(1), 33–39 (1982).
   PubMedGoogle Scholar
• Fisher BJ, Gaspar LE, Stitt LW, Noone BE. Pituitary adenoma in adolescents: a biologically more aggressive disease? Radiology192(3), 869–872 (1994).
   PubMed Web of Science ®Google Scholar
• Espay AJ, Azzarelli B, Williams LS, Bodensteiner JB. Recurrence in pituitary adenomas in childhood and adolescence. J. Child Neurol.16(5), 364–367 (2001).
   PubMed Web of Science ®Google Scholar
• Mindermann T, Wilson CB. Pituitary adenomas in childhood and adolescence. J. Pediatr. Endocrinol. Metab.8(2), 79–83 (1995).
   PubMed Web of Science ®Google Scholar
• Partington MD, Davis DH, Laws ER Jr, Scheithauer BW. Pituitary adenomas in childhood and adolescence. Results of transsphenoidal surgery. J. Neurosurg.80(2), 209–216 (1994).
   PubMed Web of Science ®Google Scholar
• Gold EB. Epidemiology of pituitary adenomas. Epidemiol. Rev.3, 163–183 (1981).
   PubMed Web of Science ®Google Scholar
• Schlechte JA. Prolactinoma. Curr. Ther. Endocrinol. Metab.6, 45–47 (1997).
   PubMedGoogle Scholar
• Schlechte JA. Clinical practice. Prolactinoma. N. Engl. J. Med.349(21), 2035–2041 (2003).
   PubMed Web of Science ®Google Scholar
• Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary8(1), 3–6 (2005).
   PubMedGoogle Scholar
• Stratakis CA, Schussheim DH, Freedman SM et al. Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J. Clin. Endocrinol. Metab.85(12), 4776–4780 (2000).
   PubMed Web of Science ®Google Scholar
• Lafferty AR, Chrousos GP. Pituitary tumors in children and adolescents. J. Clin. Endocrinol. Metab.84(12), 4317–4323 (1999).
   PubMed Web of Science ®Google Scholar
• Molitch ME, Elton RL, Blackwell RE et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J. Clin. Endocrinol. Metab.60(4), 698–705 (1985).
   PubMed Web of Science ®Google Scholar
• Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N. Engl. J. Med.331(14), 904–909 (1994).
   PubMed Web of Science ®Google Scholar
• Colao A, Arnaldi G, Beck-Peccoz P et al. Pegvisomant in acromegaly: why, when, how. J. Endocrinol. Invest.30(8), 693–699 (2007).
   PubMed Web of Science ®Google Scholar
• Schlechte JA. Long-term management of prolactinomas. J. Clin. Endocrinol. Metab.92(8), 2861–2865 (2007).
   PubMed Web of Science ®Google Scholar
• Schlechte JA, Sherman BM, Chapler FK, VanGilder J. Long term follow-up of women with surgically treated prolactin-secreting pituitary tumors. J. Clin. Endocrinol. Metab.62(6), 1296–1301 (1986).
   PubMed Web of Science ®Google Scholar
• Luedde M, Helmke B, Katus HA, Frey N. Severe mitral valve regurgitation with fatal cardiogenic shock in a patient on long-term cabergoline treatment. Int. J. Cardiol. (2008) (Epub ahead of print).
   Google Scholar
• De Bellis A, Colao A, Savoia A et al. Effect of long-term cabergoline therapy on the immunological pattern and pituitary function of patients with idiopathic hyperprolactinaemia positive for antipituitary antibodies. Clin. Endocrinol. (Oxf.) (2008) (Epub ahead of print).
   Google Scholar
• Mindermann T, Wilson CB. Age-related and gender-related occurrence of pituitary adenomas. Clin. Endocrinol. (Oxf.)41(3), 359–364 (1994).
   PubMed Web of Science ®Google Scholar
• Magiakou MA, Mastorakos G, Oldfield EH et al. Cushing’s syndrome in children and adolescents. Presentation, diagnosis, and therapy. N. Engl. J. Med.331(10), 629–636 (1994).
   PubMed Web of Science ®Google Scholar
• Batista DL, Riar J, Keil M, Stratakis CA. Diagnostic tests for children who are referred for the investigation of Cushing syndrome. Pediatrics120(3), E575–E586 (2007).
   PubMed Web of Science ®Google Scholar
• Pereira MA, Halpern A, Salgado LR et al. A study of patients with Nelson’s syndrome. Clin. Endocrinol. (Oxf.),49(4), 533–539 (1998).
   PubMed Web of Science ®Google Scholar
• Drimmie FM, MacLennan AC, Nicoll JA, Simpson E, McNeill E, Donaldson MD. Gigantism due to growth hormone excess in a boy with optic glioma. Clin. Endocrinol. (Oxf.),53(4), 535–538 (2000).
   PubMed Web of Science ®Google Scholar
• Laws ER Jr, Scheithauer BW, Carpenter S, Randall RV, Abboud CF. The pathogenesis of acromegaly. Clinical and immunocytochemical analysis in 75 patients. J. Neurosurg.63 (1), 35–38 (1985).
   PubMed Web of Science ®Google Scholar
• Pandey P, Ojha BK, Mahapatra AK. Pediatric pituitary adenoma: a series of 42 patients. J. Clin. Neurosci.12(2), 124–127 (2005).
   PubMed Web of Science ®Google Scholar
• Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J. Clin. Endocrinol. Metab.92(12), 4598–4601 (2007).
   PubMed Web of Science ®Google Scholar
• Mindermann T, Wilson CB. Pediatric pituitary adenomas. Neurosurgery36(2), 259–268; discussion 269 (1995).
   PubMed Web of Science ®Google Scholar
• Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth Hormone Research Society and the Pituitary Society. J. Clin. Endocrinol. Metab.89(7), 3099–3102 (2004).
   PubMed Web of Science ®Google Scholar
• Sheppard MC. Primary medical therapy for acromegaly. Clin. Endocrinol. (Oxf.),58(4), 387–399 (2003).
   PubMed Web of Science ®Google Scholar
• Ayuk J, Stewart SE, Stewart PM, Sheppard MC. Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clin. Endocrinol. (Oxf.),60(3), 375–381 (2004).
   PubMed Web of Science ®Google Scholar
• Jallad RS, Musolino NR, Salgado LR, Bronstein MD. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin. Endocrinol. (Oxf.),63(2), 168–175 (2005).
   PubMed Web of Science ®Google Scholar
• Bronstein MD. Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome. Front. Horm. Res.35, 129–134 (2006).
   PubMed Web of Science ®Google Scholar
• Cozzi R, Attanasio R, Montini M et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J. Clin. Endocrinol. Metab.88(7), 3090–3098 (2003).
   Google Scholar
• Gilbert J, Ketchen M, Kane P et al. The treatment of de novo acromegalic patients with octreotide-LAR: efficacy, tolerability and cardiovascular effects. Pituitary6(1), 11–18 (2003).
   PubMedGoogle Scholar
• Parkinson C, Drake WM, Roberts ME, Meeran K, Besser GM, Trainer PJ. A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. J. Clin. Endocrinol. Metab.87(4), 1797–1804 (2002).
   PubMed Web of Science ®Google Scholar
• Koop BL, Harris AG, Ezzat S. Effect of octreotide on glucose tolerance in acromegaly. Eur. J. Endocrinol.130(6), 581–586 (1994).
   PubMed Web of Science ®Google Scholar
• Trainer PJ, Drake WM, Katznelson L et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med.342(16), 1171–1177 (2000).
   PubMed Web of Science ®Google Scholar
• Feenstra J, de Herder WW, ten Have SM et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet365(9471), 1644–1646 (2005).
   PubMed Web of Science ®Google Scholar
• Main KM, Sehested A, Feldt-Rasmussen U. Pegvisomant treatment in a 4-year-old girl with neurofibromatosis type 1. Horm. Res.65(1), 1–5 (2006).
   PubMedGoogle Scholar
• Rix M, Laurberg P, Hoejberg AS, Brock-Jacobsen B. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl. Eur. J. Endocrinol.153(2), 195–201 (2005).
   PubMed Web of Science ®Google Scholar
• Pack SD, Qin LX, Pak E et al. Common genetic changes in hereditary and sporadic pituitary adenomas detected by comparative genomic hybridization. Genes Chromosomes Cancer43(1), 72–82 (2005).
   PubMed Web of Science ®Google Scholar
• Boikos SA, Stratakis CA. Carney complex: the first 20 years. Curr. Opin. Oncol.19(1), 24–29 (2007).
   PubMed Web of Science ®Google Scholar
• Thapar K, Kovacs K, Laws ER. The classification and molecular biology of pituitary adenomas. Adv. Tech. Stand. Neurosurg.22, 3–53 (1995).
   PubMedGoogle Scholar
• Elster AD. Modern imaging of the pituitary. Radiology187(1), 1–14 (1993).
   PubMed Web of Science ®Google Scholar
• Batista D, Courkoutsakis NA, Oldfield EH et al. Detection of adrenocorticotropin-secreting pituitary adenomas by magnetic resonance imaging in children and adolescents with cushing disease. J. Clin. Endocrinol. Metab.90(9), 5134–5140 (2005).
   PubMed Web of Science ®Google Scholar
• Patronas N, Bulakbasi N, Stratakis CA et al. Spoiled gradient recalled acquisition in the steady state technique is superior to conventional postcontrast spin echo technique for magnetic resonance imaging detection of adrenocorticotropin-secreting pituitary tumors. J. Clin. Endocrinol. Metab.88(4), 1565–1569 (2003).
   PubMed Web of Science ®Google Scholar
• Ram Z, Bruck B, Hadani M. Ultrasound in pituitary tumor surgery. Pituitary2(2), 133–138 (1999).
   PubMedGoogle Scholar
• Suzuki R, Asai J, Nagashima G et al. Transcranial echo-guided transsphenoidal surgical approach for the removal of large macroadenomas. J. Neurosurg.100(1), 68–72 (2004).
   PubMed Web of Science ®Google Scholar
• Lee JY, Lunsford LD, Subach BR, Jho HD, Bissonette DJ, Kondziolka D. Brain surgery with image guidance: current recommendations based on a 20-year assessment. Stereotact. Funct. Neurosurg.75(1), 35–48 (2000).
   PubMed Web of Science ®Google Scholar
• Doppman JL, Ram Z, Shawker TH, Oldfield EH. Intraoperative US of the pituitary gland. Work in progress. Radiology192(1), 111–115 (1994).
   PubMed Web of Science ®Google Scholar
• Arita K, Kurisu K, Tominaga A et al. Trans-sellar color Doppler ultrasonography during transsphenoidal surgery. Neurosurgery42(1), 81–85; discussion 86 (1998).
   PubMed Web of Science ®Google Scholar
• Ram Z, Shawker TH, Bradford MH, Doppman JL, Oldfield EH. Intraoperative ultrasound-directed resection of pituitary tumors. J. Neurosurg.83(2), 225–230 (1995).
   PubMed Web of Science ®Google Scholar
• Berkenstadt H, Perel A, Ram Z, Feldman Z, Nahtomi-Shick O, Hadani M. Anesthesia for magnetic resonance guided neurosurgery: initial experience with a new open magnetic resonance imaging system. J. Neurosurg. Anesthesiol.13(2), 158–162 (2001).
   PubMed Web of Science ®Google Scholar
• Levivier M, Wikler D, De Witte O, Van de Steene A, Baleriaux D, Brotchi J. PoleStar N-10 low-field compact intraoperative magnetic resonance imaging system with mobile radiofrequency shielding. Neurosurgery53(4), 1001–1006; discussion 1007 (2003).
   PubMed Web of Science ®Google Scholar
• Hadani M, Spiegelman R, Feldman Z, Berkenstadt H, Ram Z. Novel, compact, intraoperative magnetic resonance imaging-guided system for conventional neurosurgical operating rooms. Neurosurgery48(4), 799–807; discussion 807–809 (2001).
   PubMed Web of Science ®Google Scholar
• Muhr C. Positron emission tomography in acromegaly and other pituitary adenoma patients. Neuroendocrinology83(3–4), 205–210 (2006).
   PubMed Web of Science ®Google Scholar
• de Herder WW, Reijs AE, Kwekkeboom DJ et al.In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand. Clin. Endocrinol. (Oxf.),45(6), 755–767 (1996).
   PubMed Web of Science ®Google Scholar
• Pellegata NS, Quintanilla-Martinez L, Siggelkow H et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc. Natl Acad. Sci. USA103(42), 15558–15563 (2006).
   PubMed Web of Science ®Google Scholar
• Boikos SA, Stratakis CA. Pituitary pathology in patients with Carney complex: growth-hormone producing hyperplasia or tumors and their association with other abnormalities. Pituitary9(3), 203–209 (2006).
   PubMedGoogle Scholar
• Vierimaa O, Georgitsi M, Lehtonen R et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science312(5777), 1228–1230 (2006).
   PubMed Web of Science ®Google Scholar
• Koch G, Tiwisina T. [Contribution to the heredity of acromegaly and hyperostosis generalisata with pachyderma (chromophobe hypophysis adenoma) in father and son.] Arztl Forsch.13(1), 489–504 (1959).
   Google Scholar
• Pestell RG, Alford FP, Best JD. Familial acromegaly. Acta Endocrinol. (Copenh.)121(2), 286–289 (1989).
   PubMedGoogle Scholar
• McCarthy MI, Noonan K, Wass JA, Monson JP. Familial acromegaly: studies in three families. Clin. Endocrinol. (Oxf.)32(6), 719–728 (1990).
   PubMed Web of Science ®Google Scholar
• Carney JA, Gordon H, Carpenter PC, Shenoy BV, Go VL. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore)64(4), 270–283 (1985).
   PubMed Web of Science ®Google Scholar
• Akintoye SO, Chebli C, Booher S et al. Characterization of gsp-mediated growth hormone excess in the context of McCune–Albright syndrome. J. Clin. Endocrinol. Metab.87(11), 5104–5112 (2002).
   PubMed Web of Science ®Google Scholar
• Boikos SA, Stratakis CA. Carney complex: pathology and molecular genetics. Neuroendocrinology83(3–4), 189–199 (2006).
   PubMed Web of Science ®Google Scholar
• Kurtkaya-Yapicier O, Scheithauer BW, Carney JA et al. Pituitary adenoma in Carney complex: an immunohistochemical, ultrastructural, and immunoelectron microscopic study. Ultrastruct. Pathol.26(6), 345–353 (2002).
   PubMed Web of Science ®Google Scholar
• Melmed S, Casanueva FF, Cavagnini F et al. Guidelines for acromegaly management. J. Clin. Endocrinol. Metab.87(9), 4054–4058 (2002).
   PubMed Web of Science ®Google Scholar
• Kovacs K, Horvath E, Thorner MO, Rogol AD. Mammosomatotroph hyperplasia associated with acromegaly and hyperprolactinemia in a patient with the McCune-Albright syndrome. A histologic, immunocytologic and ultrastructural study of the surgically-removed adenohypophysis. Virchows Arch. A. Pathol. Anat. Histopathol.403(1), 77–86 (1984).
   PubMedGoogle Scholar
• Cuttler L, Jackson JA, Saeed uz-Zafar M, Levitsky LL, Mellinger RC, Frohman LA. Hypersecretion of growth hormone and prolactin in McCune-Albright syndrome. J. Clin. Endocrinol. Metab.68(6), 1148–1154 (1989).
   PubMed Web of Science ®Google Scholar
• Spada A, Lania A, Ballare E. G protein abnormalities in pituitary adenomas. Mol. Cell Endocrinol.142(1–2), 1–14 (1998).
   PubMed Web of Science ®Google Scholar
• Lee JS, FitzGibbon E, Butman JA et al. Normal vision despite narrowing of the optic canal in fibrous dysplasia. N. Engl. J. Med.347(21), 1670–1676 (2002).
   PubMed Web of Science ®Google Scholar
• Kaushik S, Smoker WR, Frable WJ. Malignant transformation of fibrous dysplasia into chondroblastic osteosarcoma. Skeletal Radiol.31(2), 103–106 (2002).
   PubMed Web of Science ®Google Scholar
• Galland F, Kamenicky P, Affres H et al. McCune-Albright syndrome and acromegaly: effects of hypothalamopituitary radiotherapy and/or pegvisomant in somatostatin analog-resistant patients. J. Clin. Endocrinol. Metab.91(12), 4957–4961 (2006).
   PubMed Web of Science ®Google Scholar
• Thakker RV, Bouloux P, Wooding C et al. Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. N. Engl. J. Med.321(4), 218–224 (1989).
   PubMed Web of Science ®Google Scholar
• Spada A. Genetic aspects of pituitary tumors. J. Pediatr. Endocrinol. Metab.14(Suppl. 5), 1213–1216; discussion 1261–1212 (2001).
   PubMedGoogle Scholar
• Chandrasekharappa SC, Teh BT. Functional studies of the MEN1 gene. J. Intern. Med.253(6), 606–615 (2003).
   PubMed Web of Science ®Google Scholar
• Bertolino P, Tong WM, Galendo D, Wang ZQ, Zhang CX. Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1. Mol. Endocrinol.17(9), 1880–1892 (2003).
   PubMed Web of Science ®Google Scholar
• Daly AF, Vanbellinghen JF, Khoo SK et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J. Clin. Endocrinol. Metab.92(5), 1891–1896 (2007).
   PubMed Web of Science ®Google Scholar
• Karhu A, Aaltonen LA. Susceptibility to pituitary neoplasia related to MEN-1, CDKN1B and AIP mutations: an update. Hum. Mol. Genet.16(1), R73–R79 (2007).
   PubMed Web of Science ®Google Scholar
• Wood PJ, Barth JH, Freedman DB, Perry L, Sheridan B. Evidence for the low dose dexamethasone test to screen for Cushing’s syndrome: recommendations for a protocol for biochemistry laboratories. Ann. Clin. Biochem.34(3), 222–229 (1997).
   PubMed Web of Science ®Google Scholar
• Nieman LK, Biller BM, Findling JW et al. The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. (2008) (Epub ahead of print).
   Google Scholar